Global Gene Synthesis Market Statistics: USD 8.3 Billion Value by 2032

Gene Synthesis Industry

Summary:

• The global gene synthesis market size reached USD 2.1 Billion in 2023.
• The market is expected to reach USD 8.3 Billion by 2032, exhibiting a growth rate (CAGR) of 16.58% during 2024-2032.
• North America leads the market, accounting for the largest gene synthesis market share.
• Solid-phase synthesis accounts for the majority of the market share in the method segment due to its high efficiency and scalability, allowing for rapid, accurate production of complex gene sequences. 
• Antibody DNA synthesis holds the largest share in the gene synthesis industry.
• Gene and cell therapy development represents the leading application segment.
• Academic and government research institutes remain a dominant segment in the market.
• The increasing use of gene synthesis in research, drug discovery, and biotechnology is a primary driver of the gene synthesis market.
• The rise of clustered, regularly interspaced short palindromic repeats (CRISPR) and other gene-editing technologies is e reshaping the gene synthesis market.

Industry Trends and Drivers:

• Expanding Applications in Research and Biotechnology:

The increasing use of gene synthesis in research, drug discovery, and biotechnology is impelling the growth of the market. Researchers leverage gene synthesis to create specific genes and deoxyribonucleic acid (DNA) sequences tailored to study disease mechanisms, develop genetic treatments, and create genetically engineered organisms. This customization capability accelerates research by allowing scientists to explore complex biological processes at a molecular level without relying on traditional DNA isolation methods. In biotechnology, gene synthesis enables the production of enzymes, proteins, and bioengineered products on a scale that meets industrial needs, making it essential in fields like biofuels, pharmaceuticals, and agriculture. As laboratories and biotech firms are increasing investments in these areas, demand for synthetic gene services is growing, improving technological advancements that reduce synthesis costs and improve accuracy.

• Advancements in CRISPR and Gene Editing Technologies:

The rise of clustered, regularly interspaced short palindromic repeats (CRISPR) and other gene-editing technologies is driving the need for synthetic genes, which serve as crucial tools in gene-editing workflows. Gene synthesis companies provide precisely engineered DNA sequences that researchers use as templates for CRISPR-based modifications. This support helps streamline genome editing projects, enabling modifications at previously unachievable scales and levels of precision. Moreover, as the application of the CRISPR spectrum broadens from therapeutic uses in genetic disorders to agricultural improvements, researchers increasingly rely on synthetic genes to facilitate experimentation and ensure consistency across studies. The synergy between gene synthesis and gene-editing technology is contributing to the market growth.

• Growing Demand for Personalized Medicine and Synthetic Biology:

Personalized medicine and synthetic biology are introducing new paradigms in healthcare, driving the demand for gene synthesis. Personalized medicine relies on understanding individual genetic profiles to tailor treatments and drug responses, which often involves synthesizing custom genes or DNA fragments for analysis. This approach is also integral to synthetic biology, where scientists engineer organisms or molecular systems for specific applications, such as creating bacteria that can digest pollutants or produce biofuels. Gene synthesis underpins these advancements by enabling highly specific DNA production, which is vital for crafting complex genetic pathways. As personalized and synthetic biology is capturing attention across industries, the demand for flexible and precise gene synthesis is growing, encouraging providers to develop more efficient synthesis methods to meet these emerging needs.

Request for a sample copy of this report: https://www.imarcgroup.com/gene-synthesis-market/requestsample

Gene Synthesis Market Report Segmentation:

Breakup By Method:

• Solid-Phase Synthesis
• Chip-Based Synthesis 
• PCR-Based Enzyme Synthesis

Solid-phase synthesis represents the largest segment due to its high efficiency and scalability, allowing for rapid, accurate production of complex gene sequences.

Breakup By Services:

• Antibody DNA Synthesi
• Viral DNA Synthesis
• Others

Antibody DNA synthesis holds the biggest market share because of the growing need for custom antibodies in medical research, diagnostics, and therapeutic development.

Breakup By Application:

• Gene and Cell Therapy Development
• Vaccine Development
• Disease Diagnosis
• Others

Gene and cell therapy development account for the majority of the market share, driven by the increasing focus on genetic treatments for complex diseases.

Breakup By End Use:

• Biotechnology and Pharmaceutical Companies
• Academic and Government Research Institutes
• Contract Research Organizations

Academic and government research institutes represent the leading segment as they drive foundational research and development across various gene synthesis applications.

Breakup By Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America enjoys the leading position attributed to its extensive government funding, advanced biotechnology infrastructure, and a strong focus on healthcare innovation.

Top Gene Synthesis Market Leaders:

The gene synthesis market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:

• ATUM
• Boster Biological Technology
• Eurofins Genomics
• Genewiz Inc. (Azenta Life Sciences)
• Genscript Biotech Corp.
• Integrated DNA Technologies Inc.
• Merck KGaA
• OriGene Technologies Inc.
• ProMab Biotechnologies Inc.
• ProteoGenix Inc
• Thermo Fisher Scientific Inc.
• Twist Bioscience

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163